Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...
As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback